RJ Hamster
BSEM: Leaving the OTC Behind? Potential Nasdaq Uplisting THIS…
 You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here. This message is from Huge Alerts.BSEM: SEVEN STRAIGHT PROFITABLE QUARTERS AND A POTENTIAL NASDAQ MOVE IN 2026!  Clinically Proven MedTech Disruptor BSEM is Separating from the Pack, Targeting a $300M+ Market, and Has a $25.50 Analyst Price Target!Greetings All,The MedTech sector sits at the intersection of innovation, necessity, and scale—and that combination makes it one of the most powerful long-term investment themes in global markets. Aging populations, rising chronic disease, and relentless healthcare demand mean spending doesn’t slow just because the economy does. Yet within MedTech, only a handful of companies combine real profitability, clinical proof, and expanding market access. BioStem Technologies (OTC: BSEM) is one of them—and as 2026 approaches, it’s a name that should not be ignored.Seven Straight Profitable Quarters in a Sector Where Most Still Burn CashBSEM just delivered another resilient quarter, reporting $10.5 million in Q3 2025 revenue, $0.8 million in GAAP net income, and $2.7 million in adjusted EBITDA—marking its seventh consecutive profitable quarter. In small-cap regenerative medicine, that kind of consistency is rare. Even with pricing pressure and reimbursement shifts, BSEM maintained an 88.5% gross margin and closed the quarter with $27.2 million in cash, reinforcing its ability to fund growth without diluting shareholders. BioREtain® Delivers Level 1 Clinical Proof—Dominates Standard of CareBioStem’s proprietary BioREtain® processing technology is the engine behind its momentum. A published Level 1 randomized controlled trial in diabetic foot ulcers showed a 53% probability of complete wound closure, compared to just 31% with standard of care—a massive clinical advantage in one of healthcare’s most expensive and dangerous chronic conditions. Conducted under FDA-level rigor and published in a peer-reviewed journal, the data validates BSEM’s claim that preserving the natural structure and growth factors of placental tissue leads to better, more durable healing. A $27 Billion Wound-Care Market with Multiple New Growth ChannelsDiabetic foot ulcers alone cost the U.S. healthcare system $9–$13 billion annually, with millions of patients at risk of infection, hospitalization, and amputation. BioStem is expanding aggressively into high-value channels, including the Department of Veteran Affairs, state Medicaid programs like Texas, hospitals, and ambulatory surgery centers. These initiatives open the door to a $300–$350 million addressable market, with broader federal and state access planned for 2026. Volume is already telling the story—product units sold jumped 40% year over year, even in a challenging pricing environment.Nasdaq Uplisting Could Be the Visibility ShockwaveBSEM is actively targeting a Nasdaq uplisting in mid-2026, following completion of KPMG audits and renewed SEC engagement. An uplisting would dramatically increase liquidity, unlock institutional ownership, and re-rate the stock alongside listed MedTech peers. With FDA-registered, AATB-accredited manufacturing, a growing patent portfolio, and national reimbursement coverage, BSEM is building the exact profile institutions look for—but hasn’t fully priced in yet.$25.50 Zacks Target Signals Significant Upside PotentialZacks Small Cap Research has placed a $25.50 price target on BSEM, reflecting confidence in its profitability, clinical validation, and expanding footprint. While reimbursement reform and pricing pressure remain short-term risks, management believes those same reforms will favor technologies that deliver proven outcomes and economic value—exactly where BioStem excels. THE BOTTOM LINEBioStem Technologies is no longer a speculative MedTech story—it’s a profitable, clinically validated growth company with expanding market access and a clear path toward greater visibility.Seven straight profitable quarters, breakthrough clinical data, new federal and state channels, and a potential Nasdaq uplisting make BSEM one of the most compelling MedTech names to watch in 2026. Start your research!  We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security.We would like to inform you that we have received or expect to receive compensation in connection with the purchase or sale of the securities of BioStem Technologies Inc. (OTC: BSEM) . The compensation consists of up to $6,500 and was received/will be received from Sideways Frequency.This compensation should not be considered as an endorsement of the securities of BioStem Technologies Inc. (OTC: BSEM) and we are not responsible for any errors or omissions in any information provided about the securities of BioStem Technologies Inc. (OTC: BSEM) by Huge Alerts.We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions.This disclosure is made as of 01/06/2026.Our mailing address is: Behind the Markets, LLC 4260 NW 1st Avenue, Suite 55 Boca Raton, FL 33431 Copyright © 2024 Behind the Markets, LLC, All rights reserved. You’re receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our Privacy Policy or our Legal Notices. Behind the Markets You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here. Today’s Bonus Content: Flu Season Stocks Are on Sale |
